Anacor Pharmaceuticals Reports 2015 Fourth Quarter and Year-End Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Jefferies Cuts Price Target on Anacor Pharma (ANAC) to $105 Following a 4Q EPS Miss
March 1, 2016 9:12 AM ESTJefferies maintained a Buy rating on Anacor Pharmaceuticals (NASDAQ: ANAC), and cut the price target to $105.00 (from $159.00), following the company's 4Q earnings report. ANAC reported an EPS loss of $0.43, missing Jefferies' estimates for a loss of $0.31. Management attributed the miss to short term competitive... More
Anacor Pharma (ANAC) Misses Q4 EPS by 13c
February 29, 2016 4:04 PM ESTAnacor Pharma (NASDAQ: ANAC) reported Q4 EPS of ($0.43), $0.13 worse than the analyst estimate of ($0.30). Revenue for the quarter came in at $21.2 million versus the consensus estimate of $27.93 million.
For earnings history and earnings-related data on Anacor Pharma (ANAC) click here.
... More